secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060462
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax appoints Aleksandra Rizo to Board; Morrison resigns; annual meeting votes passed
--------------------------------------------------------------------------------

- Aleksandra Rizo, M.D., Ph.D., elected to Board effective May 15, replacing Briggs Morrison who resigned.
- Dr. Rizo receives $45,644 annual cash for Board service, $8,558 for Science & Technology Committee, plus initial option for 35,000 shares vesting monthly over three years.
- Annual meeting results: all director nominees elected (Huber 61.9M for, Jarrett 39.5M for), executive compensation advisory vote passed (46.2M for, 16.3M against), auditor ratified (65.4M for).
- Dr. Rizo is President/CEO of Vividion, brings hematology clinical development and regulatory experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/sndx-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer